Investor Relations
Vitro Diagnostics dba Vitro Biopharma develops and commercialize adult stem cell technology for applications in stem cell research, drug development and therapeutic products for treatment a vast variety of diseases and conditions. We offer a series of tools to promote the development of stem cell research and clinical applications focusing on Mesenchymal Stem Cells (MSCs).
Become an Investor: Call (303) 999-2137
Vitro Diagnostics, Inc. (OTCPK:VODG)
Company Information
Vitro Biopharma
4621 Technology Drive
Golden, CO 80403
303-999-2130
www.vitrobiopharma.com
Investor Relations
John Evans
CFO & Director
[email protected]
(303) 999-2137
wwww.vitrobiopharma.com
Transfer Agent
Securities Transfer Corporation
2591 Dallas Parkway, Suite 102
Frisco, TX 75034
469-633-0100
www.stctransfer.com
Share Statistics
Outstanding: 46,194,200
(As of June 26th, 2018)
Press Releases
Vitro Biopharma 2018 CEO Shareholder Letter
Press Release Source: Vitro Diagnostics, Inc. Vitro Biopharma 2018 CEO Shareholder Letter:Record Revenues from Stem Cell Treatments Lead to 4th Quarter BreakevenCashflow & Growth...
read moreVitro Biopharma Receives ISO 9001 Certification of its Quality Management System
Golden, Colorado-December 12th, 2018-Vitro Diagnostics, Inc. (OTCPK: VODG), dba Vitro Biopharma (“Vitro”) one of the world’s emerging biotechnology companies focused on Umbilical Cord Mesenchymal Stem Cell (“MSC”) research and clinical products has been awarded...
read moreVitro BioPharma Engages Senior Director of Sales and Marketing
Vitro BioPharma engages Senior Director of Sales and Marketing GOLDEN, CO/ACCESSWIRE/October 23,2018/Vitro Diagnostics, Inc. (OTC PINK: VODG), dba Vitro BioPharma today announced the engagement of a senior Sales and Marketing Director. The company has engaged Keith V....
read moreVitro Biopharma 3rd Quarter Ended July 31st 2018 Financial Results of Operations.
Vitro Biopharma 3rd Quarter 2018 Financial Results of Operations Golden, Colorado-September 24th, 2018-Vitro Diagnostics, Inc. (OTCPK: VODG), dba Vitro BioPharma, announced its 3rd quarter financial results of operations, ended July 31st, 2018. Vitro Diagnostics Inc....
read moreVitro Biopharma 2nd Quarter ended April 30th 2018 Financial Results of Operations
Golden, Colorado-June, 26th, 2018-Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced its 2nd quarter ended April 30th 2018 financial results of operations. Vitro Diagnostics Inc. (“Vitro”) is pleased to announce a record 2nd quarter in Stem Cell...
read moreVitro Biopharma Debt Re-Capitalization and Executive Team Formation
Golden, Colorado-May 3rd, 2018-Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, (the “Company”) announced today the details of its balance sheet re-capitalization and the formation of its executive team effective April 30th , 2018. The Company’s founder and...
read moreVitro Biopharma 1st Quarter 2018 Financial Results of Operations
Golden, Colorado-March 20, 2018-Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced its 1st quarter ended January 31st 2018 financial results of operations. Vitro Diagnostics Inc. (“Vitro”) is pleased to announce a record 1st quarter in Stem Cell...
read more2017 CEO Shareholder Letter: Translation from R&D to Stem Cell Therapies Accelerates Revenue and Prospects for Future Growth
Golden, Colorado—December 20, 2017—Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced its CEO letter to its shareholders including discussion of 2016 & 2017 results and plans for 2018 including regenerative medicine initiatives for expanding...
read moreVitro Biopharma Files Patent for its Novel Stem Cell Line with Broad Application to Stem Cell Therapies
Golden, Colorado—November 21, 2017 —Vitro Diagnostics, Inc. (OTCPK: VODG), dba Vitro Biopharma, announced the filing of a USPTO patent application regarding a novel stem cell line and its application to treatment of a variety of conditions including skeletal muscular,...
read moreVitro Biopharma Reports Positive Clinical Trial Results of Stem Cell Activation Therapy for Autism
Golden, Colorado—August 8, 2017 —Vitro Diagnostics, Inc. (OTCPK: VODG), dba Vitro Biopharma, announced initial results of a Phase I clinical trial testing the effects of its proprietary stem cell activation compounds for safety and efficacy in autistic patients....
read more
Providing high quality commercialized cell lines, media, stem cell products & stem cell technology
Providing applications in stem cell research, drug discovery and STEM CELL therapies
Customer Service (303)-999-2130 Ext. 1
4621 Technology Drive Golden, CO 80403
Technical Support (303)-999-2130 Ext. 2
Accounting (303)-999-2130 Ext. 3
Please click the image above to view our ISO 9001:2015 Certification.
Please click the image above to view our FDA registration.